Home > Healthcare > Medical Devices > Diagnostic Devices > Glucometer Market

Glucometer Market Trends

Report ID: GMI8010
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Glucometer Market Trends

Government and organizational initiatives aimed at heightening awareness among the public regarding diabetics stimulate the growth of the market.

For instance, in India, the Ministry of Health and Family Welfare initiated a nationwide program for the prevention and control of cancer, diabetes, cardiovascular diseases, and stroke (NPCDCS). The program aims to provide education to the population at risk of these diseases, offering information on available clinical treatments and diagnostic services throughout the country.
Furthermore, the National Diabetes Prevention Program (National DPP), a collaborative effort involving public and private organizations dedicated to preventing or delaying type 2 diabetes. The program provides evidence-based interventions, including the CDC-recognized lifestyle change program, emphasizing healthy eating and physical activity.
Furthermore, the increasing adoption of self-monitoring blood glucose devices, in conjunction with product approvals for treating various life-threatening diseases, is poised to further amplify the market's growth.
Thus, aforementioned factors are anticipated to drive the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global glucometer industry was valued at around USD 16.3 billion in 2023 and is estimated to reach over USD 46.8 billion by 2032, owing to the significant increase in the prevalence of diabetes in both developed and developing economies.

The continuous glucose monitors segment garnered USD 8.9 billion in 2023 and will grow significantly through 2032 due to their real-time monitoring capabilities, providing comprehensive insights into glycemic status and enabling prompt decision-making for diabetes management.

North America glucometer market accounted for USD 6.2 billion in 2023 and is predicted to witness substantial growth over 2024-2032, attributed to the region's relatively high prevalence of diabetes, increased awareness about diabetes management, and the availability of technologically advanced glucometers.

Abbott Laboratories, AgaMatrix, All Medicus Co., Ltd., Arkray, Inc., Ascensia Diabetes Care Holdings AG, B. Braun Melsungen AG, Bionime Corporation, DarioHealth Corporation, Dexcom, Inc., Essenlife Bioscience, Inc., F. Hoffmann-La Roche Ltd., LifeScan Inc., Medtronic plc, Nova Biomedical, Inc., and Sinocare Inc.